Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

NCT00478959 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Disease

Interventions

DRUG: Lenalidomide (Revlimid®)

Sponsor

University Health Network, Toronto

Collaborators

[object Object]